Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 (Apatoliroravir / Epalutimab) plus lenvatinib as first-line therapy for advanced non-clear cell renal cell carcinoma
ChiCTR2600126556Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jun 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 and lenvatinib in non-clear cell renal cell carcinoma (nccRCC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Progression-free survival (PFS). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
QL1706lenvatinib
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on ChiCTR2600126556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126556.